

## Disclosures

### Personal Commercial (2)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Bristol-Myers Squibb Company	Speaker's Bureau	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Natera Inc	Speaker's Bureau	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (9)

Trial Name	Trial Sponsor	Trial Funding Source
3. A study to test the effect of Empagliflozin in patients who are in hospital for acute heart failure: EMPULSE trial.	Boehringer Ingelheim Pharmaceuticals, Inc	
ODYSSEY	Bristol Myers Squibb	
DISCOVER-HCM	Bristol Myesr	
Surveillance heart care registry: SHORE Registry	CareDx	
ProTECT	Natera	
Exercise in genetic cardiovascular conditions: LIVE-HCM/LQT Study	National Institutes of Health	
1. Safety and tolerability of in-hospital initiation of LCZ696 compared to Valsartan in HFpEF: PARAGLIDE HF study	Novartis Corporation	
CSP #578: "Prevention of Serious Adverse Events Following Angiography" (PRESERVE), VA Cooperative Studies Program	VA Co-operative Study Program	VA Co-operative Study Program
CSP #571: "Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty" (DIVA), VA Cooperative Studies Program	VA Co-operative Study Program	VA Co-operative Study Program

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 8/9/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement | Signed on 8/9/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo | Signed on 8/9/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

### On-Going Obligation Agreement | Signed on 8/9/2025

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.